Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer
Authors:
- Walid ShalataWalid Shalata
- Sameh DaherSDSameh Daher
- Natali Maimon RabinovitchNRNatali Maimon Rabinovitch
- Sivan ShamaiSSSivan Shamai
- Waleed KianWKWaleed Kian
- Ilit TurgemanITIlit Turgeman
- Yulia DudnikYDYulia Dudnik
- Olga KazareenOKOlga Kazareen
- Yulia RovitskyYRYulia Rovitsky
- Edmond SaboESEdmond Sabo
- Dan Levy FaberDFDan Levy Faber
- Ronen GaliliRGRonen Galili
Open Access
- 31 October 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6568
Abstract
Background: Lung cancer is among the most prevalent and serious forms of cancer, characterized by an allogenic phenotype that presents significant therapeutic challenges. Materials and Methods: We analyzed medical records from January 2022 to August 2023, focusing on individuals aged 18 and older diagnosed with resectable NSCLC who received neoadjuvant chemo-immunotherapy prior to surgical intervention. Results: The cohort comprised 56 patients, predominantly smokers (95%) and male (74%), with 80% presenting the disease at stage III. Of the participants, 44 underwent surgery, with 95% receiving lobar resection. Clinical assessments via PET-CT imaging revealed an 86% rate of response or disease stabilization, while pathological evaluations showed complete and major pathological responses in 61% of cases. Conclusions: This real-world data supports the safety and efficacy of incorporating immune checkpoint inhibitors in the neoadjuvant treatment of NSCLC, followed by surgical resection.Keywords
All Related Versions
This publication has 30 references indexed in Scilit:
- Rapid Advances in Resectable Non–Small Cell Lung CancerJAMA Oncology, 2024
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung CancerJAMA, 2024
- Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare DataClinical Lung Cancer, 2022
- Lung cancerThe Lancet, 2021
- Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparisonLung Cancer, 2021
- IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant TherapyJournal of Thoracic Oncology, 2020
- Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness studyLung Cancer, 2018
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant dataThe Lancet, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009